Abstract

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

IPC Classes  ?

• A61K 36/89 - Cyperaceae (Sedge family)
• A61K 36/75 - Rutaceae (Rue family)
• A61K 36/34 - Campanulaceae (Bellflower family)
• A61K 36/23 - Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• A61P 11/14 - Antitussive agents
• A61P 31/14 - Antivirals for RNA viruses
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

IPC Classes  ?

• A61K 36/9068 - Zingiber, e.g. garden ginger
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 11/14 - Antitussive agents
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 11/10 - Expectorants

Abstract

Provided are a traditional Chinese medicine composition for tonifying Qi, activating blood and detoxificating and use thereof. The composition is prepared from the following ingredients: 10-30 parts of sun-dried ginseng, 6-30 parts of pseudo-ginseng, and 3-15 parts of Rheum officinale. The traditional Chinese medicine composition can ameliorate the illness state of patients suffering from sepsis secondary to pulmonary infection, and the oxygen saturation of the patients is improved by means of bowel-relaxing and anti-inflammation effects, thus shortening the mechanical ventilation time of the patients.

IPC Classes  ?

• A61K 36/708 - Rheum (rhubarb)
• A61K 36/258 - Panax (ginseng)
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/04 - Antibacterial agents

Abstract

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

IPC Classes  ?

• A61K 31/365 - Lactones
• A61P 35/00 - Antineoplastic agents
• C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms

Abstract

A traditional Chinese medicine for the treatment of diabetic nephropathy, comprising the following raw materials in parts by weight: 9-30 parts of radix astragali, 6-15 parts of semen cuscutae, 5-10 parts of peach kernel, 3-10 parts of rhizoma atractylodis, 3-10 parts of dried tangerine peel, 15-30 parts of centella asiatica, and 3-10 parts of cordyceps cicadae.

IPC Classes  ?

• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61P 37/02 - Immunomodulators
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention belongs to the field of traditional Chinese medicine, and in particular, to a composition for preventing rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition for preventing rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 15-60 parts of raw Semen Coicis, 5-30 parts of Radix Angelicae Sinensis, 5-30 parts of Radix Paeoniae Alba, 1-15 parts of Herba Ephedrae, 5-30 parts of Ramulus Cinnamomi, 5-30 parts of Radix Glycyrrhizae Praeparata, 5-30 parts of Rhizoma Atractylodis, and 10-60 parts of Radix Astragali. Proved by a CIA rat model experiment, the composition for preventing rheumatoid arthritis of the present invention can obviously alleviate the joint swelling degree of a CIA rat, X ray shows that bone destruction can be improved, and a pathological section shows good effects of inhibiting synovial tissue proliferation, reducing inflammatory cell infiltration, and delaying bone and cartilage destruction, thereby achieving the effects of symptom improvement, bone protection and anti-inflammatory for the CIA rat.

IPC Classes  ?

• A61K 36/8994 - Coix (Job's tears)
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition is made from the following raw material components in parts by mass: 10-40 parts of Radix Salviae Miltiorrhizae, 15-120 parts of Rhizoma Dioscoreae Nipponicae, 15-60 parts of Radix Astragali, 5-30 parts of Radix Paeoniae Alba, 3-15 parts of Ephedra, 3-15 parts of Radix Aconiti Laterailis Prepareata, 5-30 parts of Morinda Officinalis, and 5-30 parts of honey-fried licorice root. By means of clinical tests, it is proven that said composition can alleviate the symptoms of articulation swelling and suffered by patients, control the level of inflammation and disease progression, and has potential bone protection effects.

IPC Classes  ?

• A61K 36/8945 - Dioscorea, e.g. yam, Chinese yam or water yam
• A61K 36/746 - Morinda
• A61K 36/714 - Aconitum (monkshood)
• A61K 36/71 - Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
• A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
• A61K 36/537 - Salvia (sage)
• A61K 36/484 - Glycyrrhiza (licorice)
• A61K 36/481 - Astragalus (milkvetch)
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

The present invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor and an application thereof. The composition for preventing and/or treating rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 5-30 parts Notopterygium root, 5-45 parts kadsura pepper stem, 3-20 parts of prepared aconite root, 5-30 parts of Gentiana macrophylla, 5-30 parts of ramulus mori, 5-30 parts of Angelica sinensis, 5-20 parts of Ligusticum wallichii, 3-15 parts of Costustoot, and 3-30 parts of Radix glycyrrhizae preparata. According to clinical trials, the composition for preventing and/or treating rheumatoid arthritis of the present invention can improve the symptoms of joint swelling and pain in patients, control inflammation levels and disease progression, and has potential bone protection effects.

IPC Classes  ?

• A61K 36/714 - Aconitum (monkshood)
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed in the present invention is an application of a glutaminase inhibitor in preparation of a drug for treating psoriasis. According to the present invention, in-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, comprising remarkably reducing a Baker score of a skin lesion, effectively reducing an epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67 positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing a drug for treating psoriasis.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/433 - Thiadiazoles
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 17/06 - Antipsoriatics

Abstract

A traditional Chinese medicine composition for dispelling dampness and clearing the lung, comprising the following components in parts by mass: 5-10 parts of raw ephedra, 25-30 parts of raw gypsum, 5-12 parts of bitter almonds, 10-16 parts of rhizoma anemarrhenae, 10-16 parts of bupleurum chinense, 10-16 parts of notopterygium root, 10-16 parts of rhizoma atractylodis, 10-16 parts of agastache rugosa, and 5-12 parts of medicated leaven. The traditional Chinese medicine composition can treat community-acquired pneumonia, especially viral pneumonia, or suspected COVID 19 cases. When used as a treatment drug for suspected COVID 19 cases, thetraditional Chinese medicine composition can cut off and reverse the condition and prevent the condition from getting worse.

IPC Classes  ?

• A61K 36/8964 - Anemarrhena
• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61K 36/532 - Agastache, e.g. giant hyssop
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 9/08 - Solutions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and a preparation method therefor and an application thereof. The raw materials thereof comprise: 6-15 parts of sun-dried ginseng or American ginseng, 1-6 parts of dried orange peel, 1-3 parts of Chinese olives, 3-15 parts of fresh ginger, and 250-500 parts of lean meat. The preparation method comprises adding the raw materials according to proportions, adding water, heating to boiling by big fire, cooking for 8-12 minutes, and then changing to soft fire for cooking for 40-60 minutes. The dietary therapy formula of the present invention can serve as an effective component for preparing a qi-tonifying, dampness-eliminating and sore-throat-relieving agent, which is used for preparing a drug for treating viral asymptomatic infection, influenza, acute upper respiratory tract infection, chronic pharyngitis, or weakness.

IPC Classes  ?

• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61K 36/32 - Burseraceae (Frankincense family)
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 11/00 - Drugs for disorders of the respiratory system
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 23/00 - SoupsSauces Preparation or treatment thereof
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• A23L 13/50 - Poultry products, e.g. poultry sausages
• A23L 17/00 - Food-from-the-sea productsFish productsFish mealFish-egg substitutesPreparation or treatment thereof

Abstract

Provided is a traditional Chinese medicine composition capable of removing toxins, dispelling dampness, and disinhibiting the throat, comprising the following components in parts by mass: 15-35 parts of raw Semen Coicis, 10-15 parts of Flos Lonicerae, 10-15 parts of Folium Perillae, 10-30 parts of Radix Scrophulariae, 10-20 parts of Radix Platycodi, 15-30 parts of Radix Pseudostellariae, 5-15 parts of Rhizoma Atractylodis, and 5-15 parts of Herba Pogostemonis. The composition is used for treating asymptomatic SARS-CoV-2 infection cases, symptoms such as cough, dry throat, itchy throat, sore throat, and hoarseness caused by chronic pharyngitis, and fever, cough, dry throat, itchy throat, sore throat, hoarseness, fatigue, etc. caused by influenza and acute upper respiratory tract infections.

IPC Classes  ?

• A61K 36/8994 - Coix (Job's tears)
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Provided are a traditional Chinese medicine composition and the use thereof in the preparation of a drug for treating viral diseases, especially SARS-CoV-2 asymptomatic infection cases, influenza, acute upper respiratory tract infections, and chronic pharyngitis. The traditional Chinese medicine composition comprises, in parts by mass: 25-35 parts of Ilex asprella radix, 5-10 parts of Menthae haplocalycis herba, 15-25 parts of Mume fructus and 10-20 parts of Atractylodis rhizoma.

IPC Classes  ?

• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61K 36/534 - Mentha (mint)
• A61K 36/284 - Atractylodes
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to the technical field of traditional Chinese medicines, and relates to a pharmaceutical composition for strengthening the body and treating lung diseases, comprising the following components in parts by mass: 10-30 parts of cooked aconite, 5-15 parts of dried ginger, 20-30 parts of roasted licorice, 10-20 parts of honeysuckle, 10-30 parts of spina gleditsiae, 20-45 parts of hairy fig, 10-15 parts of patchouli, and 5-15 parts of dried tangerine peel. The present invention also provides application of the pharmaceutical composition for strengthening the body and treating lung diseases in the preparation of medicines for treating COVID-19. The pharmaceutical composition for strengthening the body and treating lung diseases of the present invention may have a certain effect in reversing the progression of severe and critical diseases of COVID-19 and lowering the rate of deterioration.

IPC Classes  ?

• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in the preparation of anti-cancer drugs. The triptolide acrylate of the present invention and pharmaceutically acceptable salts thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments prove that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting cancer cell metastasis. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

IPC Classes  ?

• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
• C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
• A61K 31/365 - Lactones
• A61P 35/00 - Antineoplastic agents

Abstract

Applications of psoralen in preparing an Nrf2 inhibitor, a medicament for Nrf2 inhibition-related diseases, and an anticancer medicament. Psoralen reduces the level of Nrf2 protein expression, reduces the antioxidative stress ability of human non-small cell lung carcinoma A549 cells, and increases the proapoptotic effects of chemotherapeutic medicament cisplatin with respect to A549. Psoralen has no significant impact on animal liver and kidneys when used as a medicament.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

A novel low-toxicity tripterygium glycoside, being obtained by chemical processing tripterygium glycoside and adding triptriolide. The novel low-toxicity tripterygium glycoside can effectively alleviate renal pathological damage and proteinuria in nephrotic syndrome, improve an inflammation level of the body, and has a significant therapeutic effect on nephrotic syndrome.

IPC Classes  ?

• A61K 36/37 - Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
• A61P 37/02 - Immunomodulators
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 17/06 - Antipsoriatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The invention relates to a preparation method of new-type nanoparticles for loading emodin, which comprises: using L.A, mPEG and stannous iso caprylate to synthesize a first intermediate product; using the first intermediate product, butanedioic anhydride and 4-dimethylaminopyridine to synthesize a second intermediate product; using the second intermediate product, 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride, N-hydroxysuccinimide and chitosan to synthesize a third intermediate product; using the third intermediate product and sodium periodate to synthesize a fourth intermediate product; using the fourth intermediate product and 5-amino-2-mercapto benzimidazole to synthesize the new-type thiolated nanoparticles. The nanoparticles loaded with emodin are used for intestinal tract dose, which may enhance the nanoparticles' adhesion ability, prolong residence time of drugs on mucosal membranes, and facilitate sustained-release of drug molecules. The encapsulation efficiency after loading drugs is no less than 83.6%, the drug loading capacity is no less than 3.89%, and good water solubility and biological degradability are provided.

IPC Classes  ?

• C08K 5/378 - Sulfides containing heterocyclic rings
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08G 63/42 - Cyclic ethersCyclic carbonatesCyclic sulfitesCyclic orthoesters
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
• A61K 9/51 - Nanocapsules
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08G 63/664 - Polyesters containing oxygen in the form of ether groups derived from hydroxycarboxylic acids
• C08G 63/91 - Polymers modified by chemical after-treatment
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• G01R 33/46 - NMR spectroscopy